May 5, 2026
Episode 46: Early Detection and Personalized Care: How Cancer Screening Is Evolving
Cancer Screening Is Changing. So Are the Conversations Around It
Cancer screening is no longer a one-size-fits-all process. As research advances and guidelines evolve, both providers and patients are navigating a more complex and personalized approach to early detection.
In this first episode of the miniVHAN podcast’s series on Cancer Screening and Prevention, Ben Park, MD, director of the Vanderbilt-Ingram Cancer Center, shares insights on how cancer screening is changing and why shared decision-making is becoming essential in delivering better outcomes.
Why Screening Guidelines Are Evolving
One of the biggest shifts in cancer screening today is the move toward earlier detection, especially as more cases are being identified in younger populations.
“The screening age for colonoscopies now in this country is 45, not 50. Similarly for mammography, it has now gone to age 40,” Dr. Park reveals.
“That’s a direct result of what we’re seeing — alarmingly, there are so many younger patients getting diagnosed with those and other cancers.”
These changes are grounded in real-world data, but they also introduce new challenges.
“We now have to show that earlier detection leads to better outcomes. And that can take decades to years,” Dr. Park explains.
The Shift Toward Personalized Screening
As cancer screening evolves, the focus is shifting from broad population guidelines to more individualized care.
Rather than applying the same schedule to everyone, providers are increasingly considering the full picture of a patient’s risk.
“We’re trying to understand the totality of an individual’s risk. Putting that all together and saying, ‘You need to be screened every one year, or every three years.’”
This approach reflects a growing emphasis on precision, aligning screening strategies with each person’s unique health profile.
Patient Engagement: Moving From Compliance to Collaboration
While screening tools and guidelines continue to improve, one factor remains constant: Patient participation is critical, but it’s not always guaranteed.
“At the end of the day, the person who’s getting screened really has to want to do it.”
That’s why the role of the provider is shifting from directing decisions to guiding them.
“I try to be their advocate, their navigator, and give them enough data and information that they can make an informed choice and good quality data,” Dr. Park offers.
This kind of engagement helps build trust and supports more meaningful, informed decision-making.
The Role of Team-Based Care in Screening and Beyond
Cancer screening is often the first step in a larger care journey, and that journey depends on strong coordination across teams.
From primary care providers to specialists, each role is essential in ensuring timely and effective follow-up.
“If you have a positive finding on your mammogram, who are you gonna go to next?”
Systems that clearly define these next steps can make a significant difference in outcomes, helping patients move seamlessly from screening to diagnosis and, if needed, treatment.
What’s Next: Expanding Access Through Innovation
Looking ahead, new technologies are poised to expand access to cancer screening — especially for populations that may face barriers today.
One emerging area is blood-based testing.
“A blood test can help pick up colon cancers and that could funnel into more colonoscopies and screenings. It’s not a replacement.”
These types of tools are designed to complement, not replace, existing methods, making screening more accessible and scalable.
“Anything we can do to increase screening rates would be a huge win.”
The Bottom Line: Make It Personal and Evidence-Based
As cancer screening continues to evolve, one principle stands out: Meaningful conversations drive better outcomes.
Providers must balance personalization with evidence, ensuring patients understand both their options and the impact of their decisions.
“You have to make it personal, but you also have to give them facts that really matter.”
Because when screening happens earlier, the benefits are clear: “When we screen patients for cancer early, the outcomes are better,” Park says. “We have more cures and less toxic therapies that we have to administer. Overall, it’s a win.”
Connect with Our Guests
Professor of Medicine, Division of Hematology Oncology Director, Vanderbilt-Ingram Cancer Center, Donna S. Hall Professor of Medicine
Episode Resources
Interested in becoming a VHAN Member and joining a collaborative group of physicians, nurses and allied professionals who are transforming health care?
Learn About Membership